Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute
Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been …

Platelets have a central role in the development of arterial thrombosis and subsequent
cardiovascular events. An appreciation of this complex process has made antiplatelet …

Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become
the cornerstone of modern cardiovascular treatment. This leads to an increase in stent …

The benefits of clopidogrel in the treatment and prevention of coronary artery disease are
well established, however, not all individuals respond in the same way to clopidogrel; there …

Clopidogrel resistance has been used as one of the terms employed in the literature to
describe different degrees of ex vivo low platelet inhibition after clopidogrel administration …

The antiplatelet agent clopidogrel in combination with aspirin has been shown to reduce
thrombotic events in patients with acute coronary syndromes and/or who are undergoing …

Clopidogrel has similar efficacy as aspirin for the prevention of thrombotic vascular events
among patients with atherosclerotic vascular disease (1) and is a suitable alternative for …

Dual antiplatelet therapy combi ning aspirin and clopidogrel is the standard care for patients
who have acute coronary syndromes (ACS) or are undergoing percutaneous coronary in …

Current available data show that about 4% to 30% of patients treated with conventional
doses of clopidogrel do not display adequate antiplatelet response. Clopidogrel resistance …

Antiplatelet therapy with aspirin and clopidogrel in PCI patients, though effective, is still
associated with thrombotic complications. These are multifactorial in origin, but partially …